Mottola Leonardo

Il Dr. Leonardo Mottola si è laureato in Biologia e ha conseguito il Dottorato di Ricerca in Biochimica e la Specializzazione in Biochimica-Clinica. Dal 2006, si occupa presso il laboratorio di Epatologia di espressione genica e sequenziamento del DNA per l'analisi di mutazioni in pazienti con infezione da HCV, Steatosi epatica ed Epatocarcinoma.

Informazioni aggiuntive

  • Pubblicazioni Scientifiche:

    Totale pubblicazioni a partire dal 2011: 17


    Anno

    2014; 9(10): e110284

    Individualized treatment of genotype 1 naïve patients: an italian multicenter field practice experience.

    Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M


    2014; ():

    Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study.

    Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A


    2013; 58: S476

    Effects of a new liposome-encapsulated formulation of silybin on hepatitis c virus infection

    Ripoli M., Angelico R., Piazzolla V., Santoro R., Mottola L., Petruzzellis D., Mangia A.

    2013; 59(2): 221-8

    Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.

    Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C


    HCV2012 - 19th International Symposium on hepatitis C virus and related viruses 2012; Venezia 5-9 ottobre 2012: p 301

    Effects of silybin on Hepatitis C virus replications: an "in vitro" study

    Ripoli M, Piazzolla V, Mottola L, Santoro R, Petruzzellis D, Mangia A,

    2012; Ottobre 2012 - 1791: 1028a

    Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major tretated for chronic hepatitis C

    Santoro R, Piazzolla V, Mottola L, Dello Iacono N, Mangia A

    Therapy in Liver Diseases 2012; (): 33-38

    How can we im prove svr rates in patients with genotype 2/3 hcv infection?

    Mangia A, Mottola L

    2012; ():

    Update on the treatment of patients with non-genotype 1 HCV infection.

    Mangia A, Mottola L, Piazzolla V


    2012; 56 - 1135: s448

    IL28B CC. Genotype is associated with higher on-treatment-response rates in PTS with HCV-3: interim results of the write study

    Piazzolla V, Forte P, Francavilla R, Barbarini G, Mecenate F, Carrado M, Minerva G, Bacca D, Carretta V, Pellicelli A, Romano M, Montalto G, Zignego L, Nosotti L, De Luna A, Agostinacchio E, Cuccorese G, Luchi S, Bertino G, Santoro R, Mottola L, Petruzzel

    Current Gastroenterology Reports 2012; 14(1): 87-93

    Treatment of non-genotype 1 hepatitis C virus patients.

    Mangia A, Mottola L


    2012; 32 Suppl 1(): 135-40

    What's new in HCV genotype 2 treatment.

    Mangia A, Mottola L


    2011; 16(8): 1309-16

    IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients.

    Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I


    2011; 54: S525

    Lack of association between IL28B variants and HBSAG clearance after interferon treatment

    Mangia A, Santoro R, Mottola L, Fasano M, Minerva N, Bacca D, Piazzolla V, Carretta V, Termite A, Agostinacchio E, Facciorusso D, Petruzzellis D, Santantonio T

    2011; 54(4): 403A-404A

    Treatment Of Patients With Acute Hcv Monoinfection May Be Delayed After Week 24 According With Il28b Single Nucleotide Polymorphisms (Snp) Results And Independently Of Hepatitis C Virus (Hcv) Genotype

    Mangia A. et al.

    2011; ():

    Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring.

    Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG


    2011; 53(2): 389-95

    Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

    Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A


    2011; 54(s1): 339-340

    Genetic predictors of steatosis and fibrosis in non alcoholic fatty liver disease (NAFLD)

    Mangia A, Mottola L, Petruzzellis D, Piazzolla V, Garrubba M, Di Paola R, Santoro R, Trischitta V, Villella M, Fanelli R, Vanni E, Seripa D, Pilotto A, Bugianesi E, Guido M, Santini SA

    {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}

nuovo-css

webcamlive

Newsletter

Informativa Newsletter
  twitter   facebook   youtube